Ribbon Bio rolled out an early‑access program for a cell‑free version of its MiroSynth long‑DNA platform, offering synthetic linear DNA molecules up to ~11 kb with reported accuracy above 90% and average accuracy near 95%. The in‑vitro, bacterial‑free process yields products without endotoxin or bacterial proteins to suit cell‑and‑gene therapy, mRNA vaccine, and personalized vaccine developers. Ribbon emphasized applicability to GMP‑aligned workflows and noted pricing starting at roughly $0.35 per base pair for standard molecules. The launch reflects growing demand for longer, high‑fidelity synthetic DNA in therapeutic manufacturing and regulatory compliance. Source: Ribbon Bio commercial announcement and product datasheet.